Diversification of Treatment Solutions in the Medical Devices Business
First written in FY2017. 4 of 9 entries say "Restated". Latest entry: FY2023.
4 other companies' latest entry also says "Advanced".
- FY2023AdvancedAnnual report
「In the United States, the ultrasound renal denervation system received its first approval as a renal denervation device and a new treatment option for hypertension.」
The ultrasound renal denervation system developed by the medical device business received US approval, bringing the development of treatment solutions to the concrete commercialization stage. - FY2022AdvancedAnnual report
「In a clinical trial of an ultrasound renal denervation system being developed for uncontrolled hypertension, the primary endpoint was met and the US FDA accepted the approval application.」
In the medical device business, the ultrasound renal denervation system achieved its primary endpoint and the US FDA accepted the application, marking progress in the development of treatment solutions. - FY2022-Q3ReframedAnnual report
「As a result of concentrating the medical device business on priority projects, the company recognized impairment losses on certain tangible and intangible assets, mainly trademark rights and marketing rights, in the medical device business during the third quarter of the current consolidated fiscal year,」
For the medical device business, the company described a policy shift toward concentrating the business on priority projects, in addition to its previous direction of diversifying treatment solutions. - FY2021RestatedAnnual report
「Clinical trials for vadadustat for renal anemia in the cardiovascular and renal fields and for ultrasound renal denervation treatment devices progressed smoothly, at a pace comparable to the previous year.」
The company has continued research and development investment and clinical trials for treatment solutions, including medical devices. - FY2020RestatedAnnual report
「Clinical trials for vadadustat for renal anemia in the cardiovascular and renal fields and for ultrasound renal denervation treatment devices progressed smoothly, at a pace comparable to the previous year.」
The company has continued research and development investment and clinical trials for treatment solutions, including medical devices. - FY2019-Q3RestatedAnnual report
「R&D expenses rose to ¥153,939 million, up 12.9% year on year, due to higher development costs for AVP-786, an ultrasound renal denervation treatment device, centanafadine, Rexulti, TAS-120 and products under development by ビステラ社,」
The company has continued to invest in research and development for medical devices and products under development, including ultrasound renal denervation treatment devices. - FY2018-Q3RestatedAnnual report
「On 29 June 2018, we exercised our share acquisition option for ReCor Medical, Inc., an affiliated company engaged in the manufacture and development of medical devices in the United States, making ReCor Medical, Inc. a wholly owned subsidiary.」
The company again disclosed the conversion of ReCor Medical into a wholly owned subsidiary, explaining that progress in clinical trials for its ultrasound renal denervation device and authorization from the FDA to conduct the next trial were reasons for the acquisition. - FY2018-Q2AdvancedAnnual report
「On 29 June 2018, we exercised our share acquisition option for ReCor Medical, Inc., an affiliated company engaged in the manufacture, development and sale of medical devices in the United States, making ReCor Medical, Inc. a wholly owned subsidiary.」
The company made ReCor Medical, Inc., which develops, manufactures and sells ultrasound renal denervation devices, a wholly owned subsidiary, taking concrete steps to diversify treatment solutions through medical devices. - FY2017First statedAnnual report
「In the clinical nutrition business, we will focus on overseas expansion, particularly in Asia, while in the medical device business, we will focus on diversifying treatment solutions.」
The company first explicitly identified the diversification of treatment solutions as a measure in the medical device business.